title: Daptomycin experience in patients with human immunodeficiency virus and resistant gram-positive infections.
abstract: OBJECTIVE
  This study was conducted to evaluate the clinical experience with daptomycin in the treatment of resistant gram-positive infections (GPIs) in patients with HIV infection.
  
  
  METHODS
  Using a retrospective, multicenter, and observational registry study, investigators assessed outcomes following daptomycin therapy in 78 patients (62 efficacy evaluable) infected with HIV and with resistant GPIs.
  
  
  RESULTS
  Overall, success rates by infection type were bacteremia 91% (20 of 22), endocarditis 91% (10 of 11), and bone/joint 100% (9 of 9). Success by pathogen was 93% (39 of 42), 93% (14 of 15), and 100% (5 of 5) for methicillin-resistant Staphylococcus aureus, vancomycin-resistant enterococci, and methicillin-resistant coagulase-negative staphylococci, respectively. Daptomycin appeared to be well tolerated, with 9% having an adverse event possibly related to daptomycin and 4% discontinuing daptomycin.
  
  
  CONCLUSIONS
  In HIV-infected patients, daptomycin appears to be a useful agent for treating resistant GPIs.
authors.affiliation: Saint Michael's Medical Center, Infectious Diseases Department Newark, NJ, USA.
authors.forename: Jihad
authors.initials: J
authors.lastname: Slim
authors.affiliation: JFK Medical Center, Comprehensive Pharmacy Services Edison, NJ, USA.
authors.forename: Humberto
authors.initials: H
authors.lastname: Jimenez
authors.affiliation: Medical Affairs, Cubist Pharmaceuticals, Lexington, MA, USA.
authors.forename: Darren
authors.initials: D
authors.lastname: Culshaw
authors.affiliation: Medical Affairs, Cubist Pharmaceuticals, Lexington, MA, USA.
authors.forename: Hina
authors.initials: H
authors.lastname: Patel
authors.affiliation: Medical Affairs, Cubist Pharmaceuticals, Lexington, MA, USA kenneth.lamp@cubist.com.
authors.forename: Kenneth C
authors.initials: KC
authors.lastname: Lamp
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000900:Anti-Bacterial Agents / Q000008:administration & dosage* / Q000009:adverse effects; D017576:Daptomycin / Q000008:administration & dosage* / Q000009:adverse effects; D024881:Drug Resistance, Bacterial; D005260:Female; D006094:Gram-Positive Bacteria / Q000187:drug effects / Q000502:physiology; D016908:Gram-Positive Bacterial Infections / Q000188:drug therapy* / Q000209:etiology / Q000382:microbiology; D015658:HIV Infections / Q000150:complications*; D006801:Humans; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D055815:Young Adult
chemical_list: D000900:Anti-Bacterial Agents; D017576:Daptomycin
keywords: antibiotic; daptomycin; resistant gram-positive infection